Browse by author
Lookup NU author(s): Professor Camille CarrollORCiD
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© 2021, The Author(s). To identify predictors of 36-month follow-up quality of life (QoL) outcome after bilateral subthalamic nucleus deep brain stimulation (STN-DBS) in Parkinson’s disease (PD). In this ongoing, prospective, multicenter international study (Cologne, Manchester, London) including 73 patients undergoing STN-DBS, we assessed the following scales preoperatively and at 6-month and 36-month follow-up: PD Questionnaire-8 (PDQ-8), NMSScale (NMSS), Scales for Outcomes in PD (SCOPA)-motor examination, -activities of daily living, and -complications, and levodopa equivalent daily dose (LEDD). We analyzed factors associated with QoL improvement at 36-month follow-up based on (1) correlations between baseline test scores and QoL improvement, (2) step-wise linear regressions with baseline test scores as independent and QoL improvement as dependent variables, (3) logistic regressions and receiver operating characteristic curves using a dichotomized variable “QoL responders”/“non-responders”. At both follow-ups, NMSS total score, SCOPA-motor examination, and -complications improved and LEDD was reduced significantly. PDQ-8 improved at 6-month follow-up with subsequent decrements in gains at 36-month follow-up when 61.6% of patients were categorized as “QoL non-responders”. Correlations, linear, and logistic regression analyses found greater PDQ-8 improvements in patients with younger age, worse PDQ-8, and worse specific NMS at baseline, such as ‘difficulties experiencing pleasure’ and ‘problems sustaining concentration’. Baseline SCOPA scores were not associated with PDQ-8 changes. Our results provide evidence that 36-month QoL changes depend on baseline neuropsychological and neuropsychiatric non-motor symptoms burden. These findings highlight the need for an assessment of a wide range of non-motor and motor symptoms when advising and selecting individuals for DBS therapy.
Author(s): Jost ST, Visser-Vandewalle V, Rizos A, Loehrer PA, Silverdale M, Evans J, Samuel M, Petry-Schmelzer JN, Sauerbier A, Gronostay A, Barbe MT, Fink GR, Ashkan K, Antonini A, Martinez-Martin P, Chaudhuri KR, Timmermann L, Dafsari HS, Bhidayasiri R, Falup-Pecurariu C, Jeon B, Leta V, Borghammer P, Odin P, Schrag A, Storch A, Violante MR, Weintraub D, Adler C, Barone P, Brooks DJ, Brown R, Cantillon M, Carroll C, Coelho M, Henriksen T, Hu M, Jenner P, Kramberger M, Kumar P, Kurtis M, Lewis S, Litvan I, Lyons K, Martino D, Masellis M, Mochizuki H, Morley JF, Nirenberg M, Pagonabarraga J, Panicker J, Pavese N, Pekkonen E, Postuma R, Rosales R, Schapira A, Simuni T, Stocchi F, Subramanian I, Tagliati M, Tinazzi M, Toledo J, Tsuboi Y, Walker R
Publication type: Article
Publication status: Published
Journal: npj Parkinson's Disease
Year: 2021
Volume: 7
Online publication date: 08/06/2021
Acceptance date: 19/02/2021
Date deposited: 31/01/2024
ISSN (electronic): 2373-8057
Publisher: Nature Research
URL: https://doi.org/10.1038/s41531-021-00174-x
DOI: 10.1038/s41531-021-00174-x
Altmetrics provided by Altmetric
